ive ▁beta ▁block er , ▁is ▁well ▁toler ated ▁and ▁effective ▁for ▁treatment ▁of ▁hem ang iom as , ▁the ▁agent ▁was ▁studied ▁in ▁a ▁large , ▁random ized , ▁controlled ▁trial ▁and ▁was ▁approved ▁by ▁the ▁U . S . ▁Food ▁and ▁D rug ▁Administration ▁for ▁this ▁indic ation ▁in ▁ 2 0 1 4 . ▁ ▁Pro pr an ol ol ▁has ▁subsequently ▁become ▁the ▁first - line ▁system ic ▁medical ▁ther apy ▁for ▁treatment ▁of ▁these ▁les ions . ▁ ▁Since ▁that ▁time , ▁top ical ▁tim ol ol ▁male ate ▁in ▁addition ▁to ▁or al ▁pro pr anal ol ▁has ▁become ▁a ▁common ▁ther apy ▁for ▁infant ile ▁hem ang iom as . ▁According ▁to ▁a ▁ 2 0 1 8 ▁C och rane ▁review , ▁both ▁of ▁these ▁ther ap ies ▁have ▁demonstrated ▁benef icial ▁effects ▁in ▁terms ▁of ▁clear ance ▁of ▁hem ang iom as ▁without ▁an ▁increase ▁in ▁har ms . ▁In ▁addition , ▁ ▁no ▁difference ▁was ▁detected ▁between ▁these ▁two ▁agents ▁and ▁their ▁ability ▁to ▁reduce ▁hem ang i oma ▁size ; ▁however , ▁whether ▁ ▁a ▁difference ▁in ▁safety ▁exists ▁is ▁not ▁clear . ▁All ▁of ▁these ▁results ▁were ▁based ▁on ▁moder ate - ▁to ▁low - quality ▁evidence , ▁thus ▁further ▁random ized , ▁controlled ▁tri als ▁with ▁large ▁populations ▁of ▁children ▁are ▁needed ▁to ▁further ▁evaluate ▁these ▁ther ap ies . ▁This ▁review ▁concluded ▁that ▁for ▁now , ▁no ▁evidence ▁challeng es ▁or al ▁pro pr anal ol ▁as ▁the ▁standard